Context

• First case of COVID-19 in India was announced on 27th January 2020 in Thrissur Kerala. After October 2020, there was some relief due to the subsiding of the curve of the covid case.
• In January 2020, the Government of India approved two vaccines i.e. Astra-Zeneca's Vaccine produced by Serum Institute - Covidsheild and Bharat Biotech's indigenous vaccine - Covaxin.
• This dataset deals with these vaccinations in India and provides insights into them. The two files provide information about daily COVID-19 vaccinations throughout the country and total vaccinations in each state.
• The data was collected from Our World in Data Github repo for covid-19 and Government of India website containing Vaccinations State Data, merged with relevant attributes, and uploaded.
• Government of India also approved Russia's Sputnik V for emergency use authorization on 12th April 2021.

Content

Covid-19_India_Daywise_Vaccinations.csv

Columns: - location- Location of the vaccination(country). - date- Date in format dd-mm-yyyy. - vaccine- Name of the vaccine(s) administered in the country on that day. - source_url- Source of the information for the vaccination. - total-vaccinations- Total number of doses administered till that day. If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again. - total_vaccinations_per_hundred- total_vaccinations per 100 people in the total population. - people_vaccinated- Total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same. - people_vaccinated_per_hundred- people_vaccinated per 100 people in the total population. - people_fully_vaccinated- Total number of people who received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1. - people_fully_vaccinated_per_hundred- people_fully_vaccinated per 100 people in the total population. - daily_vaccinations- New doses administered per day. - daily_vaccinations_per_million- daily_vaccinations per 1,000,000 people in the total population. - daily_change_in_vaccinations- Change in the number of doses administered (daily_vaccinations) from the previous day.

Covid-19_Statewise_Vaccination_India.csv

Columns: - State/Union Territory- Name of the State or Union Territory. - Population (2011 census)- Population of the State/UT based on 2011 census. - 1st dose- Number of first doses that were administered. - 2nd dose- Number of second doses that were administered. - Cumulative doses administered- Total number of doses administered till date. - Percentage of people given atleast one dose- Percent of the population of the state. - Percentage of people fully vaccinated- Percent of the population of the state.

Acknowledgements

I like to specify that I am only making available to Kagglers the data that is produced and maintained by Our World in Data through their Github repo, and also the Ministry of Health and Family Welfare Government of India which provide daily vaccine stats through their website. - Our World in Data Github Repo - Ministry of Health and Family Welfare Government of India

Inspiration

From this data, what you could do is: - Visualisations about the daily vaccination trends in the country. - Which state has the fastest pace in vaccination? - Prediction of future daily vaccinations in the country.

Context

Yesterday, hopes soared that an end to the pandemic may finally be in sight after an interim analysis showed Pfizer/BioNTech's vaccine candidate provided 90 percent protection in trials. It performed much better than experts had hoped for and manufacturing has already started with Pfizer stating it hopes to supply 50 million doses in 2020 and 1.3 billion doses in 2021. Pfizer chairman and chief executive Albert Bourla said that “Today is a great day for science and humanity. The first set of results from our phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19,” adding that “we are reaching this critical milestone in our vaccine development programme at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”

The rush to develop a Covid-19 vaccine has gained traction in recent months and a representative from the Russian health ministry also claimed the country's Sputnik V is up to 90 percent effective. Great hopes have also been pinned on a coronavirus vaccine candidate being developed by the University of Oxford that successfully triggered a strong immune response in trials involving 1,077 people. Scientific journal The Lancet had published hugely promising results of Phase I/II trials in July for the University of Oxford vaccine and it provoked a T cell response within 14 days of vaccination and an antibody response within 28 days.

https://www.statista.com/chart/22325/number-of-covid-19-vaccine-candidates/

Content

Vaccines generally take years to develop but candidates are now being developed at an unprecedented pace. Nearly 200 Covid-19 vaccine candidates are now listed by the World Health Organization, according to The Guardian and several are already in advanced testing. The data shows that the bulk of candidates are in the pre-clinical stage of testing where the vaccine is given to animals to see if it triggers an immune response. 39 are in phase I trials where it is administered to a small group of people to determine whether it is safe. 18 are in phase II where the candidate is given to hundreds of people to evaluate further safety issues as well as dosage. The last stage is Phase III, of which 11 candidates are currently in, and it involves thousands of people receiving the vaccine to eliminate any final safety fears, particularly considering side effects.

Acknowledgements

Niall McCarthy, Data Journalist. https://www.statista.com/chart/22325/number-of-covid-19-vaccine-candidates/

Inspiration

Covid-19

From January 18th to August 13th, 2021, 13,804 unvaccinated and 1,156 patients who had received at least one COVID-19 vaccine dose were tested qPCR-positive for SARS-CoV-2 in our center. Among vaccinated patients, 949, 205 and 2 had received a single, two or three vaccine doses, respectively. Most patients (80.3%) had received the Pfizer-BioNTech vaccine. The SARS-CoV-2 variants infecting vaccinated patients varied over time, reflecting those circulating in the Marseille area, with a predominance of the Marseille-4/20A.EU2 variant from weeks 3 to 6, of the Alpha/20I variant from weeks 7 to 25, and of the Delta/21A variant from week 26. SARS-CoV-2 infection was significantly more likely to occur in the first 13 days post-vaccine injection in those who received a single dose (48.9%) than two doses (27.4%, p< 10–3). Among 161 patients considered as fully vaccinated, i.e., >14 days after the completion of the vaccinal scheme (one dose for Johnson and Johnson and two doses for Pfizer/BioNTech, Moderna and Sputnik vaccines), 10 (6.2%) required hospitalization and four (2.5%) died. Risks of complications increased with age in a nonlinear pattern, with a first breakpoint at 54, 33, and 53 years for death, transfer to ICU, and hospitalization, respectively. Among patients infected by the Delta/21A or Alpha/20I variants, partial or complete vaccination exhibited a protective effect with a risk divided by 3.1 for mortality in patients ≥ 55 years, by 2.8 for ICU transfer in patients ≥ 34 years, and by 1.8 for hospitalization in patients ≥ 54 years. Compared to partial vaccination, complete vaccination provided an even stronger protective effect, confirming effectiveness to prevent severe forms of COVID-19.

Infected in year: 1-2019 2-2020 3-2021

Infections: 1- Yes 2- No 3-I don't Know

Symptoms: 1-Fever , headache, muscle pain 2-Lost of taste and smell 3-Nausea, vomiting, diarrhea 4-Nothing

Vaccine: 1-Pfizer-Biontech 2-AstraZeneca 3-Moderna 4-SinoVac 5-Sputnik V 6-Johnson & Johnson Janssen 7- Null = Not Vaccinated

Number of doses: a- 1 b- 2 c- 3 d- mix

Symptoms after vaccination: 1-Nothing 2-Mild 3-Moderate 4-Sever

The efficacy of the vaccines against symptomatic, severe, and hospitalization SARS-CoV-2 infection.

BackgroundIn late 2021, the pandemic wave was dominated by the Delta SARS-CoV-2 variant in Hungary. Booster vaccines were offered for the vulnerable population starting from August 2021.MethodsThe nationwide HUN-VE 3 study examined the effectiveness and durability of primary immunization and single booster vaccinations in the prevention of SARS-CoV-2 infection, Covid-19 related hospitalization and mortality during the Delta wave, compared to an unvaccinated control population without prior SARS-CoV-2 infection.ResultsThe study population included 8,087,988 individuals who were 18–100 years old at the beginning of the pandemic. During the Delta wave, after adjusting for age, sex, calendar day, and chronic diseases, vaccine effectiveness (VE) of primary vaccination against registered SARS-CoV-2 infection was between 11% to 77% and 18% to 79% 14–120 days after primary immunization in the 16–64 and 65–100 years age cohort respectively, while it decreased to close to zero in the younger age group and around 40% or somewhat less in the elderly after 6 months for almost all vaccine types. In the population aged 65–100 years, we found high, 88.1%–92.5% adjusted effectiveness against Covid-19 infection after the Pfizer-BioNTech, and 92.2%–95.6% after the Moderna booster dose, while Sinopharm and Janssen booster doses provided 26.5%–75.3% and 72.9%–100.0% adjusted VE, respectively. Adjusted VE against Covid-19 related hospitalization was high within 14–120 days for Pfizer-BioNTech: 76.6%, Moderna: 83.8%, Sputnik-V: 78.3%, AstraZeneca: 73.8%, while modest for Sinopharm: 45.7% and Janssen: 26.4%. The waning of protection against Covid-19 related hospitalization was modest and booster vaccination with mRNA vaccines or the Janssen vaccine increased adjusted VE up to almost 100%, while the Sinopharm booster dose proved to be less effective. VE against Covid-19 related death after primary immunization was high or moderate: for Pfizer-BioNTech: 81.5%, Moderna: 93.2%, Sputnik-V: 100.0%, AstraZeneca: 84.8%, Sinopharm: 58.6%, Janssen: 53.3%). VE against this outcome also showed a moderate decline over time, while booster vaccine types restored effectiveness up to almost 100%, except for the Sinopharm booster.ConclusionsThe HUN-VE 3 study demonstrated waning VE with all vaccine types for all examined outcomes during the Delta wave and confirmed the outstanding benefit of booster vaccination with the mRNA or Janssen vaccines, and this is the first study to provide clear and comparable effectiveness results for six different vaccine types after primary immunization against severe during the Delta pandemic wave.

N: Number DM: Diabetic HT: Hypertension CoronaVac: Sinovac Astra: Oxford/AstraZeneca SputV: Sputnik v (-) = Data not available.

Immunogenicity assessment groups based on the primary and booster vaccination schemes and timeframe from the second or booster dose.